skip to content

Contract Wins and Joint Ventures

PureTech signs licensing agreement

29 August 2017 09:06

PureTech Health, a clinical-stage biopharmaceutical company, has signed an exclusive licensing agreement with Monash University for a lymphatic targeting platform (the Glyph technology).

The Glyph technology is aimed at harnessing the biology of the lymphatic system to develop novel therapeutics, including those that selectively target certain lymph nodes.

The Glyph technology will be developed by PureTech Health through its subsidiary, Glyph Biosciences.

At 9:06am: (LON:PRTC) PureTech Health Plc share price was +3.5p at 136.75p

Story provided by

Related Company: PRTC

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.